Abstract:DNA mismatch repair, known as a fundamentally biological pathway, plays key roles in maintaining genomic stability, eliminating mismatch bases and preventing both mutagenesis in the short term and cancerogenesis in the long term. Polymorphisms of MLH1 in individuals may have an effect on the DNA repair capacity and therefore on cancer risk. Recently, emerging studies have been done to evaluate the association between MLH1 -93 G/A polymorphism and cancer risk in diverse populations. However, the results remain conflicting rather than conclusive. In this meta-analysis, we assessed reported studies of association between the MLH1 -93 G/A polymorphism and cancer risk including 13 691 cancer cases and 14 068 controls from 17 published studies. A borderline significant association between the MLH1 -93 G/A polymorphism and cancer risk was observed in overall analysis [heterozygote: odds ratio (OR) = 1.15; 95% confidence interval (CI) 1.05-1.26; homozygote: OR = 1.21; 95% CI, 1.04-1.40; dominant model: OR = 1.13; 95% CI 1.01-1.26; recessive model: OR = 1.21; 95% CI 1.07-1.35, respectively]. In subgroup analysis by ethnicity, significantly increased risks were found in Asian population and mixed population but not in Caucasian population. After stratified analysis according to the quality of literature, increased cancer risks were observed in the studies of lower quality but not in the studies of higher quality. Similarly, elevated cancer risks were observed in hospital-based studies but not in population-based studies. These findings showed no persuasive evidence that MLH1 -93 G/A polymorphism was associated with an increased risk of cancer. On the conservative standpoint, well-designed population-based studies with larger sample size in different ethnic groups should be performed to further confirm these results.

The Ubiquitin Ligase UBR4 and the Deubiquitylase USP5 Modulate the Stability of DNA Mismatch Repair Protein MLH1

USP37 Regulates DNA Damage Response Through Stabilizing and Deubiquitinating BLM

OTUB1 stabilizes mismatch repair protein MSH2 by blocking ubiquitination

Regulation of MSH2 Activity by Acetylation and Ubiquitylation

Acetylation of MLH1 by CBP increases cellular DNA mismatch repair activity

Human MLH1 Protein Participates in Genomic Damage Checkpoint Signaling in Response to DNA Interstrand Crosslinks, While MSH2 Functions in DNA Repair.

A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.

Mismatch Repair Protein MSH2 Regulates Translesion DNA Synthesis Following Exposure of Cells to UV Radiation

The E3 ubiquitin ligase DTX3L and the deubiquitinase USP28 fine-tune DNA double strand repair through mutual regulation of their protein levels

Disentangling the mutational effects on protein stability and interaction of human MLH1

The association between MLH1 -93 G>A polymorphism of DNA mismatch repair and cancer susceptibility: A meta-analysis

A Selective USP1–UAF1 Inhibitor Links Deubiquitination to DNA Damage Responses

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

The ATPase Activity of MLH1 is Required to Orchestrate DNA Double-Strand Breaks and End Processing During Class Switch Recombination

The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase

The mismatch DNA repair heterodimer, hMSH2|[sol]|6, regulates BLM helicase

Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors

Dna Damage Regulates Uhrf1 Stability Via The Scf Beta-Trcp E3 Ligase

Regulation of MDM2 Stability After DNA Damage

Ubiquitin-specific Protease 7 Sustains DNA Damage Response and Promotes Cervical Carcinogenesis.

The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair